Skip to content

JBIO JBIO Prepaid & Other Current

Prepaid & Other Current at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$720.8M+12.1%
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
$34.35M+152%
Vera Therapeutics logo
Vera TherapeuticsVERA
$19.04M+17.2%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$3.91M-26.2%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$6.69M+265%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$9.52M-31.7%

Other financials

Income statement

See full
Operating income-$43.4M-85.8%
Net income-$40.4M-5.8%
EPS (diluted)-$0.57+95.3%

Balance sheet

See full
Cash & equivalents$55.1M+24.6%
Total debt$808.0K+159%
Total equity$296.5M+455%
Total assets$319.4M+312%

Cash flow

See full
Operating cash flow-$24.1M-28.4%
CapEx$3.0K
Free cash flow-$33.7M

Valuation

See full
Market cap$1.33B+318%
Enterprise value$1.28B

Returns & leverage

See full
Return on equity-132.5%+120pp
Debt / equity
Current ratio14.3×-17.7×

Where this comes from

Reported directly by JBIO in its filing.

Tagged under the XBRL concept us-gaap:PrepaidExpenseAndOtherAssetsCurrent.

The official record: JBIO’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about JBIO's prepaid & other current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is JBIO's prepaid & other current?
JBIO (JBIO) reported prepaid & other current of $7.22M in Q1 2026.
How has JBIO's prepaid & other current changed year-over-year?
JBIO's prepaid & other current increased by 521.0% year-over-year, from $1.16M to $7.22M.
What is the long-term trend for JBIO's prepaid & other current?
Over 4 years (2021 to 2025), JBIO's prepaid & other current has grown at a 15.8% compound annual growth rate (CAGR), from $10.2M to $18.32M.
What does prepaid & other current mean?
Advance payments for expenses (rent, insurance, subscriptions) plus miscellaneous current assets not classified elsewhere.